文献速递白血病

急性髓系白血病(AML)何时获取基因组数据及哪些突变重要

When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter.
PubMed 文献 · Blood Adv · 2018-01-01

本文综述了突变谱分析在急性髓系白血病(AML)中用于界定疾病生物学的作用,重点讨论拟诊中危病患者;描述了在诊断时、完全缓解时和复发时进行突变谱分析的证据,并讨论了可影响欧洲白血病网风险分层的特定突变及用于微小残留病评估的分子检测证据。

要点

  • AML患者常规检测FLT3、NPM1、CEBPA及近年TP53突变。
  • 诊断时突变谱分析有助于识别预后及可靶向突变。
  • 完全缓解时突变检测可用于评估微小残留病以预警复发。

核心结论

  • 突变谱分析已根本改变AML患者的诊疗方式,可在诊断、完全缓解和复发时提供预后、靶向治疗及临床试验资格信息。

研究设计与样本

  • 本文为综述,回顾突变谱分析在AML中界定疾病生物学的作用,重点为拟诊中危病患者。

主要发现

  • AML患者常规检测FLT3、NPM1、CEBPA及近年TP53突变。
  • 诊断时突变谱分析可识别预后和可靶向突变。
  • 完全缓解时突变检测可评估微小残留病作为复发标志。
  • 复发时突变检测可识别治疗靶点和临床试验资格。
  • 部分突变被证明可影响已建立的欧洲白血病网风险分层各分类的预后。

关键数值与推荐

  • 常规检测的突变包括FLT3、NPM1、CEBPA及近年TP53。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mutational profiling has fundamentally changed our approach to patients with acute myeloid leukemia (AML). Patients with AML are routinely profiled for the presence of mutations in FLT3, NPM1, CEBPA, and, more recently, TP53 In this chapter, we review the role of mutational profiling to help define disease biology in AML, particularly among patients with putatively intermediate-risk disease. We describe the body of evidence supporting the utility of mutational profiling when performed at the time of diagnosis (to identify prognostic and targetable mutations), at the time of complete remission (to assess minimal residual disease as a marker for relapse), and at the time of relapse (to identify therapeutic targets and eligibility for clinical trials). We further identify particular mutations that have been shown to affect prognosis across the established European LeukemiaNet risk categories and discuss which mutational events might be used to alter the approach to patient care at various time points during the disease course. We also review the evidence in support of molecular profiling for assessment of minimal/measurable residual disease and describe the current landscape of studies designed to validate this approach.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Roloff GW, Griffiths EA. When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter. Blood Adv. 2018. PMID: 30425072. doi:10.1182/bloodadvances.2018020206

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。